Press Releases

Sedana Medical AB (publ) today announces that Mikael Haag takes office as Chief Financial Officer (CFO) and member of the Executive Management Team, effective 17 June 2026. The appointment of Mikael Haag was announced on 27 January 2026. Mikael Haag succeeds...

Sedana Medical AB (publ) today announces that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the drug-device combination product isoflurane delivered via the Sedana Medical ACD Delivery System for the...

Sedana Medical AB’s annual general meeting was held on Wednesday, 27 May 2026 and the main resolutions passed were the following. Regarding full details of the resolutions, referral is made to the notice convening the general meeting and the complete...

The board of directors of Sedana Medical AB (publ) has resolved to convene an annual general meeting of shareholders to be held Wednesday, 27 May 2026. Further details on the proposals can be found in the notice convening the meeting, below. The notice...

Positive Group EBITDA despite market headwinds First quarter 2026 CEO comments Positive Group EBITDA despite market headwinds In the first quarter of 2026, we delivered positive EBITDA at Group level, despite markedly fewer patients in intensive care...

Sedana Medical AB’s (publ) Annual Report describes important events and financial information for 2025, as well as the progress the company has made on its strategic priorities during the year. “2025 was a successful year for Sedana Medical...

Sedana Medical AB (publ) plans to present its interim report for the first quarter of 2026 on Thursday April 23 at 13:30 CET. According to the financial calendar, Sedana Medical plans to publish the interim report for the first quarter 2026 on Thursday...

Sedana Medical AB (publ) today reports that the first patient has been treated in the company’s Early Access Program (EAP) in the U.S. The program is approved by the U.S. Food and Drug Administration (FDA) and provides eligible patients access to...

Positive EBITDA in our ex-US business Fourth quarter 2025 January-December 2025 CEO comments Positive EBITDA in our ex-US business 2025 marked a successful year for Sedana Medical. We achieved first-time profitability in our core business outside the...

Sedana Medical AB (publ) plans to present its interim report for the fourth quarter of 2025 on Thursday February 12 at 13:30 CET. According to the financial calendar, Sedana Medical plans to publish the interim report for the fourth quarter 2025 on Thursday...